Angle (AGL)

 

Latest News

Holding(s) in Company

RNS Number: 6884Q Angle PLC 13 September 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: ANGLE plc 1b. Please in...

Exclusive worldwide option over megakaryocyte IP

RNS Number: 5663Q Angle PLC 13 September 2017 For immediate release 13 September 2017 ANGLE plc ("the Company") EXCLUSIVE WORLDWIDE OPTION OVER MEGAKARYOCYTE INTELLECTUAL PROPERTY ANGLE signs option over patent applications filed on Barts Cancer Institute's discovery of megakaryocytes' role in cancer Megakaryocytes' pre...

Co-Marketing Partnership with QIAGEN

RNS Number: 2994Q Angle PLC 11 September 2017 For immediate release 11 September 2017 ANGLE plc ("the Company") ANGLE ANNOUNCES CO-MARKETING PARTNERSHIP WITH QIAGEN Combines ANGLE's CTC harvesting technology with QIAGEN's downstream analysis and bioinformatics capabilities for circulating tumor cell research ANGLE plc...

Broker Forecast - finnCap issues a broker note on Angle PLC

finnCap today initiates coverage of Angle PLC (LON:AGL) with a corporate investment rating and price target of 100p.

All News

DateHeadlineSource
13-09-17Holding(s) in CompanyRNS
13-09-17Exclusive worldwide option over megakaryocyte IPRNS
11-09-17Co-Marketing Partnership with QIAGENRNS
05-09-17Broker Forecast - finnCap issues a broker note on Angle PLCStockMarketWire
05-09-17ANGLE appoints Nomad StockMarketWire
05-09-17Change of AdviserRNS
04-09-17ANGLE welcomes new research on Parsortix StockMarketWire
04-09-17New Research with ParsortixRNS
27-07-17ANGLE losses widen StockMarketWire
27-07-17Preliminary ResultsRNS
20-07-17Preclinical Study Presented At Tumor Boston SummitRNS
06-07-17Notice of ResultsRNS
04-07-17ANGLE confirms successful data in cancer studies StockMarketWire
04-07-17Successful Headline Data in Ovarian Cancer StudiesRNS
15-06-17FTSE lower amid ex-divs ahead of BoE rate callStockMarketWire
15-06-17Parsortix breakthrough in prostate cancerRNS
05-06-17Parsortix success reported at ASCO, says ANGLE StockMarketWire
05-06-17Success with Parsortix in Colorectal CancerRNS
03-05-17Business UpdateRNS
04-04-17Holding(s) in CompanyRNS
03-04-17Parsortix enables analysis in head and neck cancerRNS
30-03-17Prostate Cancer UpdateRNS
13-02-17Selected for European Cancer ID ProgrammeRNS
26-01-17Interim Evaluation of Ovarian Cancer StudyRNS
26-01-17Interim ResultsRNS
06-01-17ANGLE Plc to present at the Growth and Innovation Forum 2017 in London on 31 January 2017StockMarketWire
04-01-17ANGLE schedules interims StockMarketWire
04-01-17Notice of ResultsRNS
29-12-16Our AIM tip soars 60% in 2016 Interactive Investor
28-11-16ISSUE OF SHARE OPTIONSRNS
24-11-16Result of GMRNS
04-11-16ANGLE welcomes new research supporting Parsortix StockMarketWire
04-11-16Barts Research Supports Potential Use of ParsortixRNS
01-11-16Notice of GMRNS
27-10-16Director's share purchaseRNS
07-10-16Holding(s) in CompanyRNS
04-10-16Result of AGMRNS
30-09-16ANGLE notes research results in Clinical ChemistryStockMarketWire
30-09-16Research published in Clinical ChemistryRNS
19-09-16Issue of EquityRNS

RSS feeds

  • Editorial news feed for LSE:AGL Editorial
  • Regulatory news feed for LSE:AGL Regulatory